SMD Life Sciences
Home/Scientific Insights/Custom Rabbit Monoclonal vs. Mouse Hybridoma Antibody Production in India: Affinity, QC & Scale-Up Guide
Technical Whitepaper•Published: 18 Nov 2026•12 min read•By Dr. S Paul

Custom Rabbit Monoclonal vs. Mouse Hybridoma Antibody Production in India: Affinity, QC & Scale-Up Guide

Custom Rabbit Monoclonal vs. Mouse Hybridoma Antibody Production in India: Affinity, QC & Scale-Up Guide
# Custom Rabbit Monoclonal vs. Mouse Hybridoma Antibody Production in India: Affinity, QC & Scale-Up Guide ## 1. Executive Summary & Industrial IVD Context > **Bench Selection Rule — Antibody Engineering Desk:** *If your target biomarker is under 15 kDa, shares greater than 85% sequence homology with murine orthologs, or requires sub-nanomolar dissociation constants ($K_D < 10^{-10}\,\text{M}$) in a 10-minute lateral flow window, initiating with a standard BALB/c mouse hybridoma project often burns 14 weeks before yielding low-affinity IgM clones. Moving directly to custom rabbit monoclonal antibodies or recombinant rabbit single B-cell cloning solves epitope tolerance upfront.* Across India's rapidly expanding in vitro diagnostics (IVD) and biopharma ecosystem, assay developers building next-generation chemiluminescent immunoassays (CLIA), fluorescence lateral flow cassettes, and high-sensitivity ELISA kits increasingly require **custom monoclonal antibody production** rather than off-the-shelf catalog clones. Off-the-shelf clones frequently suffer from supply discontinuation, undisclosed carrier additives (BSA or gelatin that ruin colloidal gold conjugation), or proprietary epitope overlap that prevents matched-pair sandwich formation. When commissioning a **monoclonal antibody production service**, R&D directors face two primary architectural choices: classical murine hybridoma generation versus **custom rabbit monoclonal antibodies** produced via single B-cell sorting and recombinant expression in mammalian CHO or HEK293 hosts. Both formats deliver clonal homogeneity and indefinite genetic reproducibility, yet their immunological repertoires, kinetic binding profiles, and commercial manufacturing economics differ substantially. This engineering guide details the molecular advantages of rabbit versus mouse monoclonal platforms, complete 4-phase development timelines, exact **quality control protocols used in custom antibody services**, matched-pair screening methodologies for IVD kits, and seamless scale-up from 1 mg evaluation aliquots to multi-gram commercial lots in Bangalore. For immediate turnkey project scoping, review our [Custom Monoclonal Antibody Development Service](/services/custom-monoclonal-antibody-development) or browse ready-to-ship matched pairs in our [Diagnostic Monoclonal Antibodies Catalog](/monoclonal-antibodies). --- ## 2. Why Custom Rabbit Monoclonal Antibodies Outperform Mouse Hybridomas on Difficult Targets Rabbits (*Oryctolagus cuniculus*) belong to the order *Lagomorpha*, making them evolutionarily more distant from humans and mice than mice are from rats. More importantly, rabbit B-cell maturation utilizes two distinct genetic diversification mechanisms—**somatic gene conversion** and **extensive somatic hypermutation**—within the gut-associated lymphoid tissue (GALT) rather than relying primarily on combinatorial V(D)J rearrangement as rodents do. ### 2.1 Biophysical Advantages of Rabbit IgG in Clinical Diagnostics 1. **10× to 100× Higher Intrinsic Affinity:** While typical mouse hybridoma IgG1 clones average equilibrium dissociation constants ($K_D$) in the $10^{-8}$ to $10^{-9}\,\text{M}$ range, affinity-matured rabbit monoclonal antibodies routinely achieve $K_D$ values between $10^{-10}$ and $10^{-12}\,\text{M}$ (picomolar affinity). In rapid point-of-care tests where sample transit time across the nitrocellulose test line is under 45 seconds, rapid association rate constants ($k_{on} > 10^6\,\text{M}^{-1}\text{s}^{-1}$) directly lower your analytical Limit of Detection (LoD). 2. **Superior Small-Molecule & Post-Translational Epitope Recognition:** Rabbit antibodies possess structurally distinct, flexible complementarity-determining region 3 loops (CDR-H3) and an extra inter-domain disulfide bond stabilizing the light chain. This enables sharp discrimination between single-amino-acid point mutations, phosphorylation states, small haptens (steroids, drugs of abuse, therapeutic drug monitoring analytes), and conserved viral domains. 3. **Single IgG Subclass Simplification:** Unlike mice—which express IgG1, IgG2a, IgG2b, and IgG3 subclasses with sharply differing Protein A binding strengths and isoelectric points (pI)—rabbits express a single dominant IgG subclass. Downstream Protein A affinity purification becomes uniform across every clone in a screening campaign, simplifying buffer optimization for colloidal gold and HRP conjugation. 4. **Reduced Human Anti-Mouse Antibody (HAMA) Interference:** Patient sera frequently carry endogenous HAMA triggered by murine biologics or environmental exposure, causing severe false positives in sandwich immunoassays. Pairing a capture rabbit mAb with a murine detector mAb—or deploying fully recombinant rabbit matched pairs—substantially lowers cross-species Fc bridging. For deeper interference mitigation, see our technical manual on [Eliminating Heterophilic Antibody and Rheumatoid Factor Interference in Sandwich ELISA](/insights/elisa-assay-false-positives-heterophilic-antibodies-solution). ### 2.2 Technical & Commercial Comparison Matrix: Rabbit mAb vs. Mouse Hybridoma vs. Polyclonal | Engineering Parameter | Custom Rabbit Monoclonal (Single B-Cell / Recombinant) | Custom Mouse Monoclonal (Classical Hybridoma) | Custom Rabbit Polyclonal (Antigen-Affinity Purified) | | :--- | :--- | :--- | :--- | | **Typical Affinity Range ($K_D$)** | $10^{-10}$ to $10^{-12}\,\text{M}$ (Picomolar) | $10^{-8}$ to $10^{-10}\,\text{M}$ (Nanomolar) | Mixed high-avidity polyclonal pool | | **IgG Subclasses** | Single IgG class (uniform Protein A capture) | IgG1, IgG2a, IgG2b, IgG3 (variable pI & purification) | Single IgG class | | **Small-Molecule / Hapten Success Rate** | Very High (>85% on conjugated haptens & peptides) | Moderate (45–60%; frequent carrier dominance) | High | | **Lot-to-Lot Reproducibility** | 100% genetic sequence lock (CHO/HEK293 plasmid) | High (dependent on hybridoma bank stability) | Moderate (finite per immunized animal cohort) | | **Development Timeline (Antigen to Purified IgG)** | 12 – 16 Weeks (Recombinant B-cell workflow) | 14 – 20 Weeks (Fusion, subcloning, ascites/bioreactor) | 7 – 10 Weeks (Express 45-day or Standard 70-day) | | **Recommended IVD Applications** | High-sensitivity cTnI, CLIA, IHC, phospho-specific ELISA, low-copy viral antigens | High-volume rapid test strips (Dengue NS1, Malaria, hCG, HIV p24) | Lateral flow control lines, immunoprecipitation, rapid feasibility screening | | **Commercial Scale-Up Ceiling** | Multi-kilogram via fed-batch CHO bioreactors | Multi-gram via stirred-tank or hollow-fiber bioreactors | Tens to hundreds of milligrams per rabbit | --- ## 3. Antigen Design & Immunogen Strategy: Preventing Campaign Failure Before Day 1 Over 60% of failed **custom antibody development** campaigns trace back not to immunization execution, but to flawed immunogen selection. An antibody can only recognize the three-dimensional conformational state presented to host B-cells during priming. ### 3.1 Full-Length Recombinant Protein vs. Synthetic Peptide Immunogens * **Native Conformational Diagnostics (Lateral Flow & Sandwich ELISA):** Whenever your final clinical assay detects an intact circulating biomarker in human serum, plasma, or whole blood (such as [Cardiac Troponin I Control Antigen PVBSP1401](/products/PVBSP1401) or [HIV p24 Control Antigen PVBSP104](/products/PVBSP104)), immunize with folded, carrier-free recombinant protein expressed in mammalian (HEK293/CHO) or properly refolded *E. coli* systems. Synthetic linear peptides rarely elicit antibodies capable of binding discontinuous conformational epitopes on native serum proteins. * **Isoform-Specific or Cleavage-Site Targets:** When you must distinguish two highly homologous isoforms (e.g., differentiating Dengue NS1 from Zika NS1, or free PSA from complexed PSA), design 14–18 amino acid synthetic peptides spanning the unique surface-exposed loop, verify hydrophilicity and absence of N-linked glycosylation motifs, and conjugate via a terminal cysteine residue to Keyhole Limpet Hemocyanin (KLH) using Sulfo-SMCC chemistry. * **Endotoxin & Buffer Purity Requirements:** Immunogens containing >50 EU/mg bacterial lipopolysaccharide (LPS) trigger non-specific polyclonal B-cell activation and animal toxicity, skewing antibody titers toward contaminating *E. coli* host cell proteins (HCPs). Always purify recombinant immunogens to >90% SDS-PAGE homogeneity and dialyze into sterile PBS (pH 7.4) free of sodium azide, urea (>0.5 M), or SDS. --- ## 4. Platform Engineering: Single B-Cell Cloning vs. Classical Hybridoma Fusion Modern **custom monoclonal antibody production** relies on two validated discovery engines depending on target complexity and IP requirements. ``` [ ANTIGEN DESIGN & QC (>90% PURITY) ] │ ▼ [ HOST IMMUNIZATION: 2–3 NZW RABBITS OR 5 BALB/c MICE ] (Prime + 3 Boosts | Serum Titer Gate: ELISA > 1:64,000) │ ┌───────────────────┴───────────────────┐ ▼ ▼ [ RABBIT SINGLE B-CELL CLONING ] [ MOUSE HYBRIDOMA FUSION ] • PBMC / Splenocyte isolation • Splenocyte + Sp2/0 myeloma • Antigen-specific B-cell sorting • Electrofusion / PEG fusion • Single-cell culture & ELISA screen • HAT selection (10–14 days) • Direct VH / VL RT-PCR sequencing • Limiting dilution subcloning • Transient HEK293/CHO expression • Stable clone cryopreservation │ │ └───────────────────┬───────────────────┘ ▼ [ MATCHED-PAIR SCREENING & EPITOPE BINNING ] (Checkerboard Sandwich ELISA + Lateral Flow Strip Test) │ ▼ [ PROTEIN A PURIFICATION, 8-POINT QC & BULK SCALE-UP ] ``` ### 4.1 Rabbit Single B-Cell Cloning Workflow (Sequence-Defined Recombinant mAbs) Because stable rabbit fusion partner cell lines are patented or prone to chromosomal instability, industry-leading **custom rabbit monoclonal antibodies** are generated through antigen-specific single B-cell sorting: 1. **PBMC or Splenocyte Harvest:** Peripheral blood mononuclear cells (non-terminal) or splenocytes are isolated from the highest-titer New Zealand White rabbit once indirect ELISA titers exceed 1:100,000 against native target antigen. 2. **Antigen-Positive B-Cell Enrichment:** Memory B-cells are labeled with fluorescently tagged target antigen (e.g., Alexa Fluor 647-Antigen) and sorted singly into 96-well or 384-well plates containing feeder cytokines. 3. **Functional Supernatant Screening:** After 7–10 days of single B-cell expansion, culture supernatants are screened directly on the customer's actual assay platform (direct ELISA, sandwich pairing against an existing capture clone, or lateral flow half-strip dot blot). 4. **Cognate $V_H$ and $V_L$ Amplification & Sequencing:** Positive B-cell wells undergo reverse transcription and nested PCR to capture full-length heavy-chain ($V_H$) and light-chain ($V_L$) variable sequences. Once sequenced, your monoclonal antibody is permanently preserved as digital DNA—eliminating hybridoma drift or liquid nitrogen tank loss forever. 5. **Recombinant Expression & Scale-Up:** Cloned expression vectors are transfected into suspension HEK293 (for 1–50 mg validation lots) or stable CHO pools (for multi-gram commercial manufacturing). Learn how we maximize bioreactor titers in our technical guide on [Maximizing Monoclonal Antibody Titers in Fed-Batch CHO Cell Bioreactors](/insights/cho-cell-culture-titer-optimization-fed-batch). ### 4.2 Classical Mouse Hybridoma Workflow (Cost-Optimized High-Volume IVD Clones) For high-volume rapid diagnostic tests targeting established infectious pathogens—such as [Anti-Dengue NS1 Monoclonal Antibodies (PVBSP802/PVBSP803)](/products/PVBSP802), [Anti-HIV p24 Antibodies (PVBSP105/PVBSP106)](/products/PVBSP105), or [Anti-HBsAg Matched Pairs (PVBSP401/PVBSP402)](/products/PVBSP401)—murine hybridoma electrofusion remains highly economical: * High-efficiency electrofusion yields 5×–10× more viable hybridomas than manual PEG fusion, expanding epitope diversity so both capture and detector antibodies can be harvested from a single immunization cohort. * Two sequential rounds of limiting dilution cloning confirm >98% monoclonality prior to master cell bank (MCB) cryopreservation in liquid nitrogen. --- ## 5. Step-by-Step 4-Phase Custom Monoclonal Antibody Production Timeline Commercial IVD timelines cannot tolerate open-ended academic schedules. Every **custom monoclonal** project at SMD Life Sciences operates under milestone-gated go/no-go checkpoints: | Project Phase | Duration | Key Laboratory Activities | Mandatory Milestone Gate & Client Deliverable | | :--- | :--- | :--- | :--- | | **Phase 1: Antigen QC & Immunization** | Weeks 1 – 6 | Sequence/structure review, immunogen SDS-PAGE verification, immunization of 2–3 NZW rabbits or 5 BALB/c mice (Prime + 3 Boosts) | **Gate 1:** Pre-immune vs. Test Bleed ELISA report. Proceed only when antigen-specific serum titer exceeds **1:64,000** (OD > 1.0). Client receives 0.5 mL test antisera for independent assay verification. | | **Phase 2: B-Cell Sorting / Fusion & Primary Screening** | Weeks 7 – 10 | Single B-cell culture or electrofusion, primary indirect ELISA across 1,000–4,000 wells, negative counter-screen against His-tag/BSA/homologous proteins | **Gate 2:** Top 15–30 antigen-specific positive clones selected; supernatants delivered to client for functional verification on client strips/plates. | | **Phase 3: Subcloning / $V_H$-$V_L$ Cloning & Pair Screening** | Weeks 11 – 13 | Limiting dilution subcloning (mouse) or $V_H$/$V_L$ gene synthesis into IgG expression plasmids (rabbit), full $N imes N$ checkerboard sandwich pairing | **Gate 3:** Client selects top 2–5 final monoclonal clones or validated capture-detector pairs showing highest Signal-to-Noise Ratio (SNR) and zero cross-reactivity. | | **Phase 4: Purification, 8-Point QC & Bulk Delivery** | Weeks 14 – 16 | Serum-free roller bottle / stirred-tank / CHO expression, Protein A affinity chromatography, dialysis into carrier-free PBS pH 7.4, 0.22 µm sterile filtration | **Final Delivery:** 5–50 mg purified carrier-free mAb (or gram-scale lot), Master Cell Bank vials / sequenced plasmids, and full lot-specific Certificate of Analysis (CoA). | --- ## 6. How Is Quality Control Handled in Custom Antibody Services? One of the most frequent procurement questions from diagnostic quality managers is: **"How is quality control handled in custom antibody services?"** In ISO 13485 regulated IVD manufacturing, a simple spectrophotometric $A_{280}$ concentration reading is completely inadequate. Aggregated IgG, residual Protein A leachate, or high endotoxin levels will silently destroy colloidal gold conjugation and cause false-positive bands three months into stability testing. ### 6.1 Mandatory 8-Parameter Industrial Antibody QC & CoA Matrix | QC Assay Parameter | Analytical Instrumentation | Industrial IVD Acceptance Criterion | Why It Protects Your Diagnostic Assay | | :--- | :--- | :--- | :--- | | **1. Protein Concentration** | UV-Vis Spectrophotometry ($A_{280}$, $\varepsilon = 1.38 - 1.43$) + BCA cross-check | Target ± 5% (typically 1.0 – 5.0 mg/mL) | Guarantees reproducible striping density (µg/cm) on nitrocellulose membranes | | **2. Chemical Purity (Intact & Reduced)** | Reducing & Non-Reducing SDS-PAGE (4–12% Bis-Tris, Coomassie) | **≥ 95% purity** (clean ~50 kDa Heavy & ~25 kDa Light chains) | Confirms absence of albumin carryover, serum proteins, or proteolytic clipping | | **3. Monomeric Integrity / Aggregation** | Analytical Size-Exclusion HPLC (SEC-HPLC, TSKgel G3000SWXL) | **≥ 95% monomer peak** (< 5% high-molecular-weight aggregates) | Prevents gold nanoparticle crashing, conjugate flocculation, and background streaking | | **4. Binding Titer & Specific Activity** | Direct / Indirect ELISA against native antigen ($EC_{50}$ curve) | $EC_{50} < 50\,\text{ng/mL}$ (or client-defined LoD benchmark) | Verifies intact Fab paratope activity post-acid elution from Protein A | | **5. Endotoxin Content** | Kinetic Chromogenic LAL Assay (USP <85>) | **< 1.0 EU/mg** (standard IVD) or **< 0.1 EU/mg** (cell-based/in vivo) | Essential for functional cytokine assays, cellular assays, and long-term liquid stability | | **6. Specificity & Cross-Reactivity** | Counter-screen ELISA against related pathogens / structural isoforms | **< 1% cross-reactivity** at 100× clinical cut-off concentration | Eliminates clinical false positives (e.g., Dengue vs. Chikungunya/Zika; cTnI vs. cTnT) | | **7. Formulation & Carrier-Free Verification** | pH meter, conductivity, 0.22 µm bioburden check | 10 mM PBS, pH 7.4 ± 0.1; **0% BSA, 0% gelatin, 0% glycerol** | Ready for immediate passive gold adsorption, EDC/NHS latex coupling, or biotin/HRP labeling | | **8. Lot-to-Lot Reproducibility** | Parallel potency comparison against Master Reference Standard | Inter-lot potency **CV ≤ 5.0%** | Enables seamless regulatory compliance under CDSCO and EU IVDR Annex XIII | To preserve Protein A column selectivity across repeated multi-gram production batches without resin leaching, our purification team follows strict [Protein A Affinity Chromatography Resin CIP Protocols](/insights/downstream-protein-a-chromatography-resin-fouling-cip). --- ## 7. Matched-Pair Screening for Lateral Flow & Sandwich ELISA A single high-affinity antibody is only half the requirement for a sandwich diagnostic kit. Capture and detector antibodies must bind **non-overlapping, spatially distinct epitopes** simultaneously without steric hindrance. ### 7.1 Full $N imes N$ Checkerboard Pairing Protocol When a custom campaign yields 10 candidate clones (C1 through C10), we execute an automated 10 × 10 pairing matrix (100 directional combinations): 1. **Directional Testing Matters:** Clone A as immobilized capture + Clone B as HRP/gold detector frequently produces 3×–5× stronger signal than Clone B capture + Clone A detector. Polystyrene adsorption or nitrocellulose immobilization alters epitope orientation, so both orientations must be tested empirically. 2. **Matrix Spiking Validation:** Top 5 pairs from buffer testing are immediately challenged in **pooled normal human serum, EDTA plasma, and heparinized whole blood** spiked at 3× clinical LoD. Pairs that lose >25% recovery in plasma due to matrix interference or complement masking are disqualified before scale-up. 3. **Hook Effect Stress Testing:** High-concentration analyte spikes (100×–1,000× clinical cut-off) verify that the pair maintains clear positive reads without premature prozone signal drop. --- ## 8. Commercial Scale-Up in India: From 1 mg Trial to Multi-Gram Supply Once your custom clone or matched pair passes R&D verification, transitioning to commercial kit production requires predictable cost-per-milligram economics and uninterrupted cold-chain continuity: * **Pilot Validation Stage (10 mg – 100 mg):** Delivered in 2–3 weeks via high-density suspension culture, shipped carrier-free in sterile screw-cap cryovials at 2°C–8°C or dry ice across India within 24–48 hours. * **Commercial IVD Manufacturing Stage (250 mg – 10+ Grams):** Produced in serum-free fed-batch bioreactors with complete batch manufacturing records (BMR), TSE/BSE-free certification, and lot reservation agreements so your production line never experiences out-of-stock delays. * **Need Ready-Validated Pairs Today?** Before launching a 14-week custom build, verify whether SMD Life Sciences already stocks your target in our [70-SKU IVD Catalog](/products)—including high-affinity [Cardiac Troponin I Matched mAbs (PVBSP1402/PVBSP1403)](/products/PVBSP1402), [Dengue NS1 Pairs (PVBSP802/PVBSP803)](/products/PVBSP802), and [HIV p24 mAbs (PVBSP105/PVBSP106)](/products/PVBSP105). --- ## 9. Troubleshooting Custom Monoclonal Campaigns: 7-Mode Decision Matrix | Failure Mode Observed | Root Cause Mechanism | Corrective Engineering Intervention | | :--- | :--- | :--- | | **1. High Serum Titer, Zero Sandwich Pairs** | Immunodominant single epitope causing all clones to compete for the exact same binding site | Repeat screening using competitive epitope blocking (pre-saturate antigen with dominant clone before sorting secondary B-cells) | | **2. Antibody Works in ELISA, Fails on Lateral Flow** | Slow association rate ($k_{on} < 10^5\,\text{M}^{-1}\text{s}^{-1}$) cannot capture antigen during 30-second capillary transit | Switch from mouse hybridoma to **custom rabbit monoclonal antibodies** screened specifically for fast $k_{on}$ kinetics on half-strips | | **3. Heavy Aggregation After Protein A Elution** | Acid sensitivity during pH 2.8 glycine elution causing Fc unfolding | Elute with gentle 0.1 M Sodium Citrate (pH 3.5) directly into 1.0 M Tris-HCl (pH 9.0) neutralization buffer; add 50 mM L-Arginine stabilizer | | **4. Clone Recognizes Recombinant Antigen Only, Not Patient Serum** | Immunogen expressed in *E. coli* lacked native human disulfide bridges or mammalian glycosylation | Re-immunize with mammalian HEK293-expressed native antigen or screen clones directly against verified positive clinical serum panels | | **5. Gradual Titer Loss in Hybridoma Subclones** | Chromosomal instability / overgrowth by non-secreting hybridoma sub-populations | Immediately perform RT-PCR sequencing of $V_H$/$V_L$ chains and convert to sequence-locked recombinant CHO expression | | **6. High Background on Negative Human Plasma** | Cross-reactivity with human serum albumin, complement, or HAMA | Incorporate negative counter-screening against pooled human negative serum during Phase 2 selection | | **7. Poor Colloidal Gold Conjugation Efficiency** | Buffer pH mismatch relative to clone pI, or residual amine-containing Tris/glycine buffer | Dialyze exhaustively into 10 mM Borate or 10 mM PBS; determine clone pI by cIEF and conjugate at pI + 0.5 pH units | --- ## 10. Ready to Launch Your Custom Monoclonal Antibody Project? Whether you require picomolar **custom rabbit monoclonal antibodies** for high-sensitivity cardiac/oncology platforms or cost-optimized murine hybridoma matched pairs for high-volume Indian rapid test manufacturing, our Bangalore R&D team delivers transparent milestone gates and industrial ISO-grade CoA documentation. * **Explore Turnkey Milestones & Pricing:** [Custom Monoclonal Antibody Development Service](/services/custom-monoclonal-antibody-development) * **Need Faster 45-Day Turnaround?** Compare with our [Custom Rabbit Polyclonal Antibody Production Service](/services/custom-polyclonal-antibody-production) * **Browse Ready-to-Ship Bulk mAbs:** [Diagnostic Monoclonal Antibodies Catalog](/monoclonal-antibodies)

Need Specific Lot CoA or Matched Antibody Pairs?

Our Electronic City, Bangalore scientific coordination desk provides lot-specific analytical data, 1 mg–5 mg evaluation samples, and custom conjugation support for IVD kit manufacturers.

Continue Reading • R&D Knowledge Base

More IVD Manufacturing Whitepapers & Formulation SOPs

View All Whitepapers →
Solving High Background Noise and False Positives in Lateral Flow Immunoassays
8 min read

Solving High Background Noise and False Positives in Lateral Flow Immunoassays

Read Technical SOP →
Eliminating Heterophilic Antibody and Rheumatoid Factor Interference in Sandwich ELISA
9 min read

Eliminating Heterophilic Antibody and Rheumatoid Factor Interference in Sandwich ELISA

Read Technical SOP →
Why Carrier-Free Recombinant Antigens Drastically Improve Gold and Latex Conjugation
6 min read

Why Carrier-Free Recombinant Antigens Drastically Improve Gold and Latex Conjugation

Read Technical SOP →